keeping up with the bence- joneses · 2019-11-06 · keeping up with the bence-joneses ... learning...
TRANSCRIPT
![Page 1: Keeping Up With The Bence- Joneses · 2019-11-06 · Keeping Up With The Bence-Joneses ... Learning Objectives •review the pathophysiology of multiple myeloma ... •describe the](https://reader030.vdocument.in/reader030/viewer/2022040819/5e675fd6c7faf865e914b07a/html5/thumbnails/1.jpg)
Keeping Up With The Bence-Joneses
Dr Leonard MinukSeptember 29, 2019
![Page 2: Keeping Up With The Bence- Joneses · 2019-11-06 · Keeping Up With The Bence-Joneses ... Learning Objectives •review the pathophysiology of multiple myeloma ... •describe the](https://reader030.vdocument.in/reader030/viewer/2022040819/5e675fd6c7faf865e914b07a/html5/thumbnails/2.jpg)
Presenter Disclosure• Faculty / Speaker’s name: Leonard Minuk
• Relationships with commercial interests:– Grants/Research Support: Clinical trials funding through GSK,
Merck, Celgene, Janssen, Onyx, BMS, Millenium– Speakers Bureau/Honoraria: None– Consulting Fees: None– Other: None
![Page 3: Keeping Up With The Bence- Joneses · 2019-11-06 · Keeping Up With The Bence-Joneses ... Learning Objectives •review the pathophysiology of multiple myeloma ... •describe the](https://reader030.vdocument.in/reader030/viewer/2022040819/5e675fd6c7faf865e914b07a/html5/thumbnails/3.jpg)
Disclosure of Financial Support• I am not aware of any financial support or in kind support for this
program
• Potential for conflict(s) of interest:– I have received no funding for this program
![Page 4: Keeping Up With The Bence- Joneses · 2019-11-06 · Keeping Up With The Bence-Joneses ... Learning Objectives •review the pathophysiology of multiple myeloma ... •describe the](https://reader030.vdocument.in/reader030/viewer/2022040819/5e675fd6c7faf865e914b07a/html5/thumbnails/4.jpg)
Mitigating Potential Bias• I will not be endorsing any specific preferred therapies for
myeloma but will show our local treatment algorithm
![Page 5: Keeping Up With The Bence- Joneses · 2019-11-06 · Keeping Up With The Bence-Joneses ... Learning Objectives •review the pathophysiology of multiple myeloma ... •describe the](https://reader030.vdocument.in/reader030/viewer/2022040819/5e675fd6c7faf865e914b07a/html5/thumbnails/5.jpg)
Learning Objectives• review the pathophysiology of multiple myeloma • interpret free light chain escape results and assess
treatment response• differentiate between MGUS versus multiple myeloma • describe the standard of care for the treatment of
multiple myeloma • list new potential agents for the treatment of multiple
myeloma
![Page 6: Keeping Up With The Bence- Joneses · 2019-11-06 · Keeping Up With The Bence-Joneses ... Learning Objectives •review the pathophysiology of multiple myeloma ... •describe the](https://reader030.vdocument.in/reader030/viewer/2022040819/5e675fd6c7faf865e914b07a/html5/thumbnails/6.jpg)
• A bone marrow cancer characterized by uncontrolled proliferation of clonal plasma cells
• Disease manifests with CRAB symptoms
– C – Hypercalcemia
– R – Renal Failure
– A – Anemia
– B – Bone disease – lytic lesions/bone fractures
What is Multiple Myeloma?
![Page 7: Keeping Up With The Bence- Joneses · 2019-11-06 · Keeping Up With The Bence-Joneses ... Learning Objectives •review the pathophysiology of multiple myeloma ... •describe the](https://reader030.vdocument.in/reader030/viewer/2022040819/5e675fd6c7faf865e914b07a/html5/thumbnails/7.jpg)
![Page 8: Keeping Up With The Bence- Joneses · 2019-11-06 · Keeping Up With The Bence-Joneses ... Learning Objectives •review the pathophysiology of multiple myeloma ... •describe the](https://reader030.vdocument.in/reader030/viewer/2022040819/5e675fd6c7faf865e914b07a/html5/thumbnails/8.jpg)
Canadian Cancer Society Statistics 2015
Epidemiology of Multiple Myeloma
• 1% of all cancers and 15% of hematologic malignancies
• ~2,700 new cases in Canada in 2015 (estimated 80 new cases in Manitoba)
• Prevalence of ~7,500 across Canada
• Median age at diagnosis of 69 years
• Incurable malignancy characterized by multiple relapses
![Page 9: Keeping Up With The Bence- Joneses · 2019-11-06 · Keeping Up With The Bence-Joneses ... Learning Objectives •review the pathophysiology of multiple myeloma ... •describe the](https://reader030.vdocument.in/reader030/viewer/2022040819/5e675fd6c7faf865e914b07a/html5/thumbnails/9.jpg)
Canadian Cancer Society 2016
![Page 10: Keeping Up With The Bence- Joneses · 2019-11-06 · Keeping Up With The Bence-Joneses ... Learning Objectives •review the pathophysiology of multiple myeloma ... •describe the](https://reader030.vdocument.in/reader030/viewer/2022040819/5e675fd6c7faf865e914b07a/html5/thumbnails/10.jpg)
Bence Jones, Phil Trans R Soc Lond 1848
![Page 11: Keeping Up With The Bence- Joneses · 2019-11-06 · Keeping Up With The Bence-Joneses ... Learning Objectives •review the pathophysiology of multiple myeloma ... •describe the](https://reader030.vdocument.in/reader030/viewer/2022040819/5e675fd6c7faf865e914b07a/html5/thumbnails/11.jpg)
Sarah Newbury 39 female, first reported case of myeloma in 1844
![Page 12: Keeping Up With The Bence- Joneses · 2019-11-06 · Keeping Up With The Bence-Joneses ... Learning Objectives •review the pathophysiology of multiple myeloma ... •describe the](https://reader030.vdocument.in/reader030/viewer/2022040819/5e675fd6c7faf865e914b07a/html5/thumbnails/12.jpg)
What is a monoclonal gammopathy?• A monoclonal immunoglobulin detected in the serum
or urine during laboratory investigation (SPEP, UPEP, serum free light chain assay)
• This immunoglobulin can be an intact Ig molecule or a free light chain
• Secreted by clonally expanded plasma cells• Many synonyms:
– M-protein, M-peak, M-band, myeloma protein, paraprotein
![Page 13: Keeping Up With The Bence- Joneses · 2019-11-06 · Keeping Up With The Bence-Joneses ... Learning Objectives •review the pathophysiology of multiple myeloma ... •describe the](https://reader030.vdocument.in/reader030/viewer/2022040819/5e675fd6c7faf865e914b07a/html5/thumbnails/13.jpg)
![Page 14: Keeping Up With The Bence- Joneses · 2019-11-06 · Keeping Up With The Bence-Joneses ... Learning Objectives •review the pathophysiology of multiple myeloma ... •describe the](https://reader030.vdocument.in/reader030/viewer/2022040819/5e675fd6c7faf865e914b07a/html5/thumbnails/14.jpg)
Serum Protein ElectroPhoresis (SPEP) • Serum protein migrate into bands
based on their size and charge• Limitations:
– Not sensitive when M-protein is small
– Cannot classify type of M-protein
![Page 15: Keeping Up With The Bence- Joneses · 2019-11-06 · Keeping Up With The Bence-Joneses ... Learning Objectives •review the pathophysiology of multiple myeloma ... •describe the](https://reader030.vdocument.in/reader030/viewer/2022040819/5e675fd6c7faf865e914b07a/html5/thumbnails/15.jpg)
Serum immunofixation • Used to determine clonality
– Monoclonal versus polyclonal• Not able to quantitate the
concentration of the M band• Must be done in conjunction with the
SPEP– Does not give the concentration of
the M-protein
![Page 16: Keeping Up With The Bence- Joneses · 2019-11-06 · Keeping Up With The Bence-Joneses ... Learning Objectives •review the pathophysiology of multiple myeloma ... •describe the](https://reader030.vdocument.in/reader030/viewer/2022040819/5e675fd6c7faf865e914b07a/html5/thumbnails/16.jpg)
SPEP – interpretation • Normal
– No M protein present
![Page 17: Keeping Up With The Bence- Joneses · 2019-11-06 · Keeping Up With The Bence-Joneses ... Learning Objectives •review the pathophysiology of multiple myeloma ... •describe the](https://reader030.vdocument.in/reader030/viewer/2022040819/5e675fd6c7faf865e914b07a/html5/thumbnails/17.jpg)
• Polyclonal gammopathy
– Liver disease– Connective tissue disease– Chronic infection
Polyclonal pattern
SPEP – interpretation
Normal
![Page 18: Keeping Up With The Bence- Joneses · 2019-11-06 · Keeping Up With The Bence-Joneses ... Learning Objectives •review the pathophysiology of multiple myeloma ... •describe the](https://reader030.vdocument.in/reader030/viewer/2022040819/5e675fd6c7faf865e914b07a/html5/thumbnails/18.jpg)
SPEP - Interpretation• Monoclonal gammopathy
![Page 19: Keeping Up With The Bence- Joneses · 2019-11-06 · Keeping Up With The Bence-Joneses ... Learning Objectives •review the pathophysiology of multiple myeloma ... •describe the](https://reader030.vdocument.in/reader030/viewer/2022040819/5e675fd6c7faf865e914b07a/html5/thumbnails/19.jpg)
SPEP - Interpretation• Monoclonal gammopathy
![Page 20: Keeping Up With The Bence- Joneses · 2019-11-06 · Keeping Up With The Bence-Joneses ... Learning Objectives •review the pathophysiology of multiple myeloma ... •describe the](https://reader030.vdocument.in/reader030/viewer/2022040819/5e675fd6c7faf865e914b07a/html5/thumbnails/20.jpg)
N = 46,739
MGUS57% (26,552)
MultipleMyeloma
18% (8,336)
AL amyloidosis9.5% (4,490)
Lymphoproliferative SMM 4% (1,780)3% (1,410) Solitary or extramedullary
plasmacytoma 2% (899)Macro 2.5% (1,236)
Other 4% (2,036)
Mayo Clinic 1960-2002
N=46,739
![Page 21: Keeping Up With The Bence- Joneses · 2019-11-06 · Keeping Up With The Bence-Joneses ... Learning Objectives •review the pathophysiology of multiple myeloma ... •describe the](https://reader030.vdocument.in/reader030/viewer/2022040819/5e675fd6c7faf865e914b07a/html5/thumbnails/21.jpg)
MGUS SMM MM
M protein in serum <30g/l and M protein >30g/l and / or
Any level of M protein (none in non-secretory) and
Clonal BMPC <10% and Clonal BMPC >10% and Clonal BMPC >10% and
No myeloma related “CRAB” No myeloma related “CRAB Myeloma related “CRAB”
No evidence of other B cell LPD or light chain associated Amyloidosis or other tissue damage
Or :BM plasma cells >60%FLCR >100>1 focal lesion on MRI
Rajkumar et al. 2014 Lancet Oncology
![Page 22: Keeping Up With The Bence- Joneses · 2019-11-06 · Keeping Up With The Bence-Joneses ... Learning Objectives •review the pathophysiology of multiple myeloma ... •describe the](https://reader030.vdocument.in/reader030/viewer/2022040819/5e675fd6c7faf865e914b07a/html5/thumbnails/22.jpg)
Rajkumar et al. 2014 Lancet Oncology
![Page 23: Keeping Up With The Bence- Joneses · 2019-11-06 · Keeping Up With The Bence-Joneses ... Learning Objectives •review the pathophysiology of multiple myeloma ... •describe the](https://reader030.vdocument.in/reader030/viewer/2022040819/5e675fd6c7faf865e914b07a/html5/thumbnails/23.jpg)
Types of Myeloma
• Intact immunoglobulin myeloma (~80%)– Production of intact immunoglobulins (M-protein)– IgG > IgA > IgD >>>> IgM– Commonly called myeloma
• Light chain myeloma (~15-20%)– Production of only light chains– Sometimes called light chain disease
• Nonsecretory myeloma (~3%)– M-protein is not present on SPEP, IFE, UPEP, uIFE, or SFLCR
![Page 24: Keeping Up With The Bence- Joneses · 2019-11-06 · Keeping Up With The Bence-Joneses ... Learning Objectives •review the pathophysiology of multiple myeloma ... •describe the](https://reader030.vdocument.in/reader030/viewer/2022040819/5e675fd6c7faf865e914b07a/html5/thumbnails/24.jpg)
• If only SPEP/IFE is done – about 15-20% of myeloma /other disorders WILL BE MISSED because SPEP will be negative– Including light chain myeloma, AL amyloidosis, light chain
deposition disease
• What can be done about this?– Urine protein electrophoresis (UPEP)– Serum free light chain ratio (SFLCR)
Beyond the SPEP
![Page 25: Keeping Up With The Bence- Joneses · 2019-11-06 · Keeping Up With The Bence-Joneses ... Learning Objectives •review the pathophysiology of multiple myeloma ... •describe the](https://reader030.vdocument.in/reader030/viewer/2022040819/5e675fd6c7faf865e914b07a/html5/thumbnails/25.jpg)
UPEP vs FLCUPEP
• Reabsorption of light chains in the tubules limits sensitivity
• 24 urine collection• Slow turn around time• Labour intensive• Compliance with testing 5-
40%
FLC
• Can be done on same sample as SPEP
• Rapid turnaround• Higher sensitivity• More prognostic information
Am J Clin Pathol 2013;140:890-897Blood 2016 :blood-2016-07-726778; doi:10.1182
![Page 26: Keeping Up With The Bence- Joneses · 2019-11-06 · Keeping Up With The Bence-Joneses ... Learning Objectives •review the pathophysiology of multiple myeloma ... •describe the](https://reader030.vdocument.in/reader030/viewer/2022040819/5e675fd6c7faf865e914b07a/html5/thumbnails/26.jpg)
Serum Free Light Chain Assay
Katzmann et al Clin Chem. 2002;428-44
![Page 27: Keeping Up With The Bence- Joneses · 2019-11-06 · Keeping Up With The Bence-Joneses ... Learning Objectives •review the pathophysiology of multiple myeloma ... •describe the](https://reader030.vdocument.in/reader030/viewer/2022040819/5e675fd6c7faf865e914b07a/html5/thumbnails/27.jpg)
Normal range for sFLC ratio rises with renal insufficiency (up to about 3)
Hutchison et al Clin J Am Soc Nephrol 2008
![Page 28: Keeping Up With The Bence- Joneses · 2019-11-06 · Keeping Up With The Bence-Joneses ... Learning Objectives •review the pathophysiology of multiple myeloma ... •describe the](https://reader030.vdocument.in/reader030/viewer/2022040819/5e675fd6c7faf865e914b07a/html5/thumbnails/28.jpg)
Free light chain interpretation - reactive
• 85 year old• Hemoglobin 93
![Page 29: Keeping Up With The Bence- Joneses · 2019-11-06 · Keeping Up With The Bence-Joneses ... Learning Objectives •review the pathophysiology of multiple myeloma ... •describe the](https://reader030.vdocument.in/reader030/viewer/2022040819/5e675fd6c7faf865e914b07a/html5/thumbnails/29.jpg)
Free light chain interpretation - CKD• 68 year old with diabetic nephropathy, now on
dialysis
![Page 30: Keeping Up With The Bence- Joneses · 2019-11-06 · Keeping Up With The Bence-Joneses ... Learning Objectives •review the pathophysiology of multiple myeloma ... •describe the](https://reader030.vdocument.in/reader030/viewer/2022040819/5e675fd6c7faf865e914b07a/html5/thumbnails/30.jpg)
Free light chain interpretation – myeloma
• 69 year old admitted with AKI, creatinine 600s• SPEP negative
![Page 31: Keeping Up With The Bence- Joneses · 2019-11-06 · Keeping Up With The Bence-Joneses ... Learning Objectives •review the pathophysiology of multiple myeloma ... •describe the](https://reader030.vdocument.in/reader030/viewer/2022040819/5e675fd6c7faf865e914b07a/html5/thumbnails/31.jpg)
Screening for plasma cell disorders
Clin Chem Lab Med 2016;54(6):907-919
![Page 32: Keeping Up With The Bence- Joneses · 2019-11-06 · Keeping Up With The Bence-Joneses ... Learning Objectives •review the pathophysiology of multiple myeloma ... •describe the](https://reader030.vdocument.in/reader030/viewer/2022040819/5e675fd6c7faf865e914b07a/html5/thumbnails/32.jpg)
• IMWG recommends SPEP and FLC as screening test for myeloma and other plasma cell dyscrasias (UPEP not necessary)
• AL amyloidosis may still require 24 hour UPEP for optimal sensitivity– 4% of AL amyloid patients missed by using only SPEP and FLC – Detected by UPEP– IMWG recommends SPEP/UPEP/FLC to screen for AL amyloidosis (therefore
may still be done for work up of nephrotic syndrome)
• UPEP on spot urine not necessary– FLC recommended in place
Take Home Message
Rajkumar et al. 2014 Lancet Oncology; 15:e538-48Clinical Chemistry 55:3 (2009)
![Page 33: Keeping Up With The Bence- Joneses · 2019-11-06 · Keeping Up With The Bence-Joneses ... Learning Objectives •review the pathophysiology of multiple myeloma ... •describe the](https://reader030.vdocument.in/reader030/viewer/2022040819/5e675fd6c7faf865e914b07a/html5/thumbnails/33.jpg)
Case Example• 54 male previously health presents to HSC ER with 2 week
history of fatigue/generalized weakness, hip/low back pain, chest pain
• WBC 9.4, Hb 70, MCV 93.3, plt 154 (normal differential)• Cr 157, LDH 345, ferritin 487• Seen by GI and endoscopy normal• Admit to family medicine short stay
![Page 34: Keeping Up With The Bence- Joneses · 2019-11-06 · Keeping Up With The Bence-Joneses ... Learning Objectives •review the pathophysiology of multiple myeloma ... •describe the](https://reader030.vdocument.in/reader030/viewer/2022040819/5e675fd6c7faf865e914b07a/html5/thumbnails/34.jpg)
Case Continued• Family MD concerned re unexplained severe anemia and AKI so
ordered further investigations• Calcium 3.52, albumin 21, B2 microglobulin 7.3, total protein
109• IgG 64, IgA 0.48, IgM 0.26• SPEP 56 g/L, immunofixation shows IgG kappa monoclonal• Serum FLC assay: free kappa 1890, free lambda 7.24, ratio 261
![Page 35: Keeping Up With The Bence- Joneses · 2019-11-06 · Keeping Up With The Bence-Joneses ... Learning Objectives •review the pathophysiology of multiple myeloma ... •describe the](https://reader030.vdocument.in/reader030/viewer/2022040819/5e675fd6c7faf865e914b07a/html5/thumbnails/35.jpg)
![Page 36: Keeping Up With The Bence- Joneses · 2019-11-06 · Keeping Up With The Bence-Joneses ... Learning Objectives •review the pathophysiology of multiple myeloma ... •describe the](https://reader030.vdocument.in/reader030/viewer/2022040819/5e675fd6c7faf865e914b07a/html5/thumbnails/36.jpg)
![Page 37: Keeping Up With The Bence- Joneses · 2019-11-06 · Keeping Up With The Bence-Joneses ... Learning Objectives •review the pathophysiology of multiple myeloma ... •describe the](https://reader030.vdocument.in/reader030/viewer/2022040819/5e675fd6c7faf865e914b07a/html5/thumbnails/37.jpg)
Hematology Consulted• Bone marrow biopsy
– Hypercellular marrow, 69% plasma cell infiltration– FISH cytogenetics: 1q duplication, trisomy 8, monosomy 13
and 14• Skeletal Survey:• “The pelvic osseous structures somewhat heterogeneous. There is suggestion of
some lucent lesionswithin the iliac wings and inferior pubic rami as well as in the proximal femoral and humeral head. Correlation with bone scan is recommended. There is a fracture the left posterolateral 2nd rib”
• Diagnosis: R-ISS stage III multiple myeloma
![Page 38: Keeping Up With The Bence- Joneses · 2019-11-06 · Keeping Up With The Bence-Joneses ... Learning Objectives •review the pathophysiology of multiple myeloma ... •describe the](https://reader030.vdocument.in/reader030/viewer/2022040819/5e675fd6c7faf865e914b07a/html5/thumbnails/38.jpg)
Treatment• IV saline and zoledronic acid to control hypercalcemia• Short course of dexamethasone• Transfused 2 units PRBC• Sent home shortly after as calcium normalized
![Page 39: Keeping Up With The Bence- Joneses · 2019-11-06 · Keeping Up With The Bence-Joneses ... Learning Objectives •review the pathophysiology of multiple myeloma ... •describe the](https://reader030.vdocument.in/reader030/viewer/2022040819/5e675fd6c7faf865e914b07a/html5/thumbnails/39.jpg)
Outpatient Treatment• Continued monthly zoledronic acid• CyBor-D chemotherapy (cyclophosphamide, bortezomib and
dexamethasone) X 4 cycles• Radiotherapy 800cGy in 1 fraction to whole pelvis and
lumbosacral spine for pain control• Achieved a VGPR with M protein reducing to 1 g/L• Sent for autologous stem cell transplant• Post transplant trace IgG kappa M protein on SPEP and normal
sFLC assay
![Page 40: Keeping Up With The Bence- Joneses · 2019-11-06 · Keeping Up With The Bence-Joneses ... Learning Objectives •review the pathophysiology of multiple myeloma ... •describe the](https://reader030.vdocument.in/reader030/viewer/2022040819/5e675fd6c7faf865e914b07a/html5/thumbnails/40.jpg)
![Page 41: Keeping Up With The Bence- Joneses · 2019-11-06 · Keeping Up With The Bence-Joneses ... Learning Objectives •review the pathophysiology of multiple myeloma ... •describe the](https://reader030.vdocument.in/reader030/viewer/2022040819/5e675fd6c7faf865e914b07a/html5/thumbnails/41.jpg)
Follow Up• Bloodwork monitored monthly• Originally planned for standard lenalidomide maintenance but
deferred due to patient reasons• 6 months post transplant:
– Kappa free light chains• 15 -> 27 -> 47 -> 116 -> 165
– SPEP remained unchanged (trace IgG kappa)– Drop in Hb from 120 to 90 (no change in Ca, Cr, or new
bone lesions)
![Page 42: Keeping Up With The Bence- Joneses · 2019-11-06 · Keeping Up With The Bence-Joneses ... Learning Objectives •review the pathophysiology of multiple myeloma ... •describe the](https://reader030.vdocument.in/reader030/viewer/2022040819/5e675fd6c7faf865e914b07a/html5/thumbnails/42.jpg)
IMWG Progressive Disease
Lancet Oncol 2016; 17: e328–46
• Increase by 25% from lowest confirmed response in any of the following:• Serum M-protein (absolute increase ≥5 g/L)
• Urine M-protein (absolute increase of ≥200 mg/24 hours)
• Bone marrow plasma cell percentage
• >10 percent increase
• Difference in the kappa and lambda FLC levels
• FLC ratio must be abnormal and
• absolute change must be >100 mg/L)
![Page 43: Keeping Up With The Bence- Joneses · 2019-11-06 · Keeping Up With The Bence-Joneses ... Learning Objectives •review the pathophysiology of multiple myeloma ... •describe the](https://reader030.vdocument.in/reader030/viewer/2022040819/5e675fd6c7faf865e914b07a/html5/thumbnails/43.jpg)
IMWG Clinical Relapse
Lancet Oncol 2016; 17: e328–46
• New soft tissue plasmacytoma or definite increase in size of existing plasmacytoma
• New bone lesions
• Hypercalcemia (Calcium > 2.8mmol/L)
• Decrease in hemoglobin by 20g/L (not related to therapy or other causes)
• Rise in serum creatinine above 177 umol/L or eGFR <40
• Hyperviscosity related to the paraprotein
![Page 44: Keeping Up With The Bence- Joneses · 2019-11-06 · Keeping Up With The Bence-Joneses ... Learning Objectives •review the pathophysiology of multiple myeloma ... •describe the](https://reader030.vdocument.in/reader030/viewer/2022040819/5e675fd6c7faf865e914b07a/html5/thumbnails/44.jpg)
Non Secretory and Light Chain Escape• Non-secretory escape
– Intact immunoglobulin at diagnosis but progression without increase in immunoglobulin or light chain
– Diagnosed by evidence of symptomatic disease (“CRAB”) and bone marrow biopsy showing increased plasma cells
– 1-2% of cases
• Light chain escape– Intact immunoglobulin at diagnosis but progression without increase
in immunoglobulin and detected by increase in light chains (by UPEP or sFLC assay)
– 1-2% of cases
![Page 45: Keeping Up With The Bence- Joneses · 2019-11-06 · Keeping Up With The Bence-Joneses ... Learning Objectives •review the pathophysiology of multiple myeloma ... •describe the](https://reader030.vdocument.in/reader030/viewer/2022040819/5e675fd6c7faf865e914b07a/html5/thumbnails/45.jpg)
![Page 46: Keeping Up With The Bence- Joneses · 2019-11-06 · Keeping Up With The Bence-Joneses ... Learning Objectives •review the pathophysiology of multiple myeloma ... •describe the](https://reader030.vdocument.in/reader030/viewer/2022040819/5e675fd6c7faf865e914b07a/html5/thumbnails/46.jpg)
Keats et al. Blood 2012; 120: 1067-76
![Page 47: Keeping Up With The Bence- Joneses · 2019-11-06 · Keeping Up With The Bence-Joneses ... Learning Objectives •review the pathophysiology of multiple myeloma ... •describe the](https://reader030.vdocument.in/reader030/viewer/2022040819/5e675fd6c7faf865e914b07a/html5/thumbnails/47.jpg)
Case Continued• Currently on second line therapy with KRD
(carfilzomib, lenalidomide, dexamethasone) with reducing light chains
![Page 48: Keeping Up With The Bence- Joneses · 2019-11-06 · Keeping Up With The Bence-Joneses ... Learning Objectives •review the pathophysiology of multiple myeloma ... •describe the](https://reader030.vdocument.in/reader030/viewer/2022040819/5e675fd6c7faf865e914b07a/html5/thumbnails/48.jpg)
Eligible for ASCT(Age <70 and good health)
Not eligible for ASCT(Age >70 or serious
comorbidity)
CBD X 4 cycles (cyclophosphamide, bortezomib, dexamethasone)
+ASCT (MEL 200)
Lenalidomide Maintenance(B maintenance for high risk cytogenetics)
CBD X 9 cycles
Progression
Lenalidomide and dexamethasonePlus one of:carfilzomib or daratumumab
1. Pomalidomide and dexamethasone2. Carfilzomib and dexamethasone
Lenalidomide+Dexamethasone until
progression
Progression
Bortezomib and dexamethasonePlus one of:Cyclophosphamide or daratumumab
![Page 49: Keeping Up With The Bence- Joneses · 2019-11-06 · Keeping Up With The Bence-Joneses ... Learning Objectives •review the pathophysiology of multiple myeloma ... •describe the](https://reader030.vdocument.in/reader030/viewer/2022040819/5e675fd6c7faf865e914b07a/html5/thumbnails/49.jpg)
Staging and Prognosis
Palumbo et al. JCO 2015;33:2863-9
![Page 50: Keeping Up With The Bence- Joneses · 2019-11-06 · Keeping Up With The Bence-Joneses ... Learning Objectives •review the pathophysiology of multiple myeloma ... •describe the](https://reader030.vdocument.in/reader030/viewer/2022040819/5e675fd6c7faf865e914b07a/html5/thumbnails/50.jpg)
`+
4.6 years 6.1 years
Kumar et al. Leukemia 2014;1122-28
- Mayo clinic 1038 patients diagnosed with myeloma between 2001 and 2010; median follow up of 5.9 years
- Current estimated OS is 6-8 years
-<1960 median OS <12 months
- 1960-1994 median OS 30 months
- 1994-2000 median OS 36 months
8+ years??
2018
![Page 51: Keeping Up With The Bence- Joneses · 2019-11-06 · Keeping Up With The Bence-Joneses ... Learning Objectives •review the pathophysiology of multiple myeloma ... •describe the](https://reader030.vdocument.in/reader030/viewer/2022040819/5e675fd6c7faf865e914b07a/html5/thumbnails/51.jpg)
Take Home Messages• 1) Order a serum protein electrophoresis AND a serum free
light chain assay when suspecting a diagnosis of myeloma• 2) There is limited utility to urine protein electrophoresis in
the diagnosis and follow up of myeloma• 3) Myeloma patients on treatment and in long-term follow up
should have BOTH SPEP and sFLC assays to monitor for disease relapse
![Page 52: Keeping Up With The Bence- Joneses · 2019-11-06 · Keeping Up With The Bence-Joneses ... Learning Objectives •review the pathophysiology of multiple myeloma ... •describe the](https://reader030.vdocument.in/reader030/viewer/2022040819/5e675fd6c7faf865e914b07a/html5/thumbnails/52.jpg)
Take Home Messages• 4) Differential diagnosis of monoclonal gammopathy
– MGUS, smoldering myeloma, multiple myeloma, plasmacytoma, AL amyloidosis, B cell lymphoproliferative disorder
• 5) How to differentiate MGUS from smoldering myeloma from symptomatic myeloma– CRAB and biomarkers
![Page 53: Keeping Up With The Bence- Joneses · 2019-11-06 · Keeping Up With The Bence-Joneses ... Learning Objectives •review the pathophysiology of multiple myeloma ... •describe the](https://reader030.vdocument.in/reader030/viewer/2022040819/5e675fd6c7faf865e914b07a/html5/thumbnails/53.jpg)
Question and Answer